secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001157523-23-001660
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock Q3 net loss $42.4M; SAPPHIRE enrollment complete, topline Q4 2024
------------------------------------------------------------------------------

- Net loss $42.4M (vs $43.3M YoY); no revenue; cash $218.6M + $92.5M Oct offering extends runway into H2 2025.
- Completed enrollment of Phase 3 SAPPHIRE trial for apitegromab in SMA; topline data expected Q4 2024.
- Expanding into cardiometabolic with SRK-439; plans Phase 2 trial with apitegromab + GLP-1 RA in 2024.
- Phase 1 DRAGON trial of SRK-181 showed 21.4% ORR in ccRCC; enrollment completion in Dec 2023.
- Completed $98M public offering in October 2023; proceeds support pipeline expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323001660/0001157523-23-001660-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000115752323001660/a53761938.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001660

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer